Zurcher Kantonalbank Zurich Cantonalbank lowered its position in shares of Boston Scientific Corporation (NYSE:BSX) by 14.6% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 330,704 shares of the medical equipment provider’s stock after selling 56,692 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Boston Scientific Corporation were worth $9,167,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the stock. HPM Partners LLC purchased a new stake in Boston Scientific Corporation during the first quarter worth about $2,718,000. Capital Fund Management S.A. raised its stake in Boston Scientific Corporation by 533.5% in the first quarter. Capital Fund Management S.A. now owns 523,318 shares of the medical equipment provider’s stock worth $13,015,000 after buying an additional 440,717 shares in the last quarter. DekaBank Deutsche Girozentrale raised its stake in Boston Scientific Corporation by 50.5% in the first quarter. DekaBank Deutsche Girozentrale now owns 317,348 shares of the medical equipment provider’s stock worth $7,855,000 after buying an additional 106,533 shares in the last quarter. Diamond Hill Capital Management Inc. raised its stake in Boston Scientific Corporation by 0.3% in the first quarter. Diamond Hill Capital Management Inc. now owns 3,361,258 shares of the medical equipment provider’s stock worth $83,594,000 after buying an additional 9,850 shares in the last quarter. Finally, Sumitomo Mitsui Trust Holdings Inc. raised its stake in Boston Scientific Corporation by 0.3% in the first quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 4,026,475 shares of the medical equipment provider’s stock worth $100,138,000 after buying an additional 12,586 shares in the last quarter. Institutional investors and hedge funds own 90.52% of the company’s stock.

Shares of Boston Scientific Corporation (BSX) opened at 27.08 on Thursday. Boston Scientific Corporation has a one year low of $19.67 and a one year high of $28.51. The firm’s 50-day moving average is $27.08 and its 200 day moving average is $26.22. The firm has a market capitalization of $37.16 billion, a P/E ratio of 48.44 and a beta of 1.09.

Boston Scientific Corporation (NYSE:BSX) last issued its quarterly earnings data on Thursday, July 27th. The medical equipment provider reported $0.32 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.31 by $0.01. The firm had revenue of $2.26 billion for the quarter, compared to analyst estimates of $2.21 billion. Boston Scientific Corporation had a return on equity of 23.62% and a net margin of 9.04%. The business’s quarterly revenue was up 6.2% compared to the same quarter last year. During the same period last year, the company earned $0.27 EPS. Equities research analysts predict that Boston Scientific Corporation will post $1.26 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: This piece was published by Watch List News and is owned by of Watch List News. If you are viewing this piece on another website, it was illegally copied and reposted in violation of United States and international copyright & trademark laws. The original version of this piece can be accessed at https://www.watchlistnews.com/zurcher-kantonalbank-zurich-cantonalbank-reduces-stake-in-boston-scientific-corporation-bsx/1533726.html.

BSX has been the topic of a number of research analyst reports. Zacks Investment Research downgraded shares of Boston Scientific Corporation from a “buy” rating to a “hold” rating in a research report on Thursday, June 29th. BMO Capital Markets reaffirmed a “buy” rating and set a $30.00 price objective on shares of Boston Scientific Corporation in a research report on Wednesday, June 21st. Royal Bank Of Canada reaffirmed an “ourperform” rating and set a $29.00 price objective (down from $31.00) on shares of Boston Scientific Corporation in a research report on Friday, June 9th. Needham & Company LLC boosted their price objective on shares of Boston Scientific Corporation from $30.00 to $32.00 and gave the company a “buy” rating in a research report on Thursday, June 22nd. Finally, BidaskClub raised shares of Boston Scientific Corporation from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 10th. One research analyst has rated the stock with a sell rating, five have issued a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $30.06.

In related news, SVP Wendy Carruthers sold 12,433 shares of Boston Scientific Corporation stock in a transaction that occurred on Thursday, August 3rd. The stock was sold at an average price of $26.75, for a total transaction of $332,582.75. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, SVP John Bradley Sorenson sold 2,100 shares of Boston Scientific Corporation stock in a transaction that occurred on Monday, July 31st. The shares were sold at an average price of $27.15, for a total value of $57,015.00. Following the sale, the senior vice president now owns 18,880 shares in the company, valued at $512,592. The disclosure for this sale can be found here. Insiders have sold 197,625 shares of company stock worth $5,409,193 over the last 90 days. 0.74% of the stock is currently owned by corporate insiders.

Boston Scientific Corporation Company Profile

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX).

Institutional Ownership by Quarter for Boston Scientific Corporation (NYSE:BSX)

Receive News & Ratings for Boston Scientific Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.